NCT01959711

Brief Summary

Laparoscopic adrenalectomy has become the gold standard operation for non-malignant adrenal tumors replacing open adrenalectomy. The most popular lateral transperitoneal laparoscopic adrenalectomy (LTLA) approach has been recently challenged by an increasing popularity of the posterior retroperitoneoscopic adrenalectomy (PRA) approach which is believed by many surgeons as an easy to learn, reproducible and beneficial for patients. However, this belief is not evidence-based, so far. The aim of this study is to clarify if PRA is superior to the LTLA as minimally invasive approach to small and benign adrenal tumors.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P25-P50 for phase_4

Timeline
Completed

Started Jan 2006

Longer than P75 for phase_4

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2006

Completed
2.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2008

Completed
5.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2013

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

October 6, 2013

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 10, 2013

Completed
Last Updated

October 10, 2013

Status Verified

October 1, 2013

Enrollment Period

2.4 years

First QC Date

October 6, 2013

Last Update Submit

October 8, 2013

Conditions

Keywords

Lateral transperitoneal laparoscopic adrenalectomyPosterior retroperitoneoscopic adrenalectomy

Outcome Measures

Primary Outcomes (1)

  • duration of surgery

    intraoperatively

Secondary Outcomes (3)

  • postoperative recovery

    participants will be followed for the duration of hospital stay, an expected average of 7 days

  • blood loss

    participants will be followed for the duration of hospital stay, an expected average of 7 days

  • postoperative complications

    up to 5 years after surgery

Study Arms (2)

Posterior RA

EXPERIMENTAL

Posterior retroperitoneoscopic adrenalectomy

Procedure: Posterior RA

Lateral transperitoneal LA

ACTIVE COMPARATOR

Lateral transperitoneal laparoscopic adrenalectomy

Procedure: Lateral transperitoneal LA

Interventions

Posterior RAPROCEDURE

Posterior retroperitoneoscopic adrenalectomy

Posterior RA

Lateral transperitoneal laparoscopic adrenalectomy

Lateral transperitoneal LA

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • unilateral adrenal tumor below 7cm in diameter without suspicion for malignancy

You may not qualify if:

  • active malignancy
  • pregnancy or lactation
  • age below 18 years, or above 80 years
  • high-risk patients according to the American Society of Anesthesiology (ASA 4 grade or higher
  • inability to comply with the scheduled follow-up protocol

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jagiellonian University, Medical College, Third Chair of General Surgery

Krakow, 31-202, Poland

Location

Related Publications (7)

  • Barczynski M, Konturek A, Golkowski F, Cichon S, Huszno B, Peitgen K, Walz MK. Posterior retroperitoneoscopic adrenalectomy: a comparison between the initial experience in the invention phase and introductory phase of the new surgical technique. World J Surg. 2007 Jan;31(1):65-71. doi: 10.1007/s00268-006-0083-8.

    PMID: 17180554BACKGROUND
  • Lee CR, Walz MK, Park S, Park JH, Jeong JS, Lee SH, Kang SW, Jeong JJ, Nam KH, Chung WY, Park CS. A comparative study of the transperitoneal and posterior retroperitoneal approaches for laparoscopic adrenalectomy for adrenal tumors. Ann Surg Oncol. 2012 Aug;19(8):2629-34. doi: 10.1245/s10434-012-2352-0. Epub 2012 Apr 20.

    PMID: 22526902BACKGROUND
  • Perrier ND, Kennamer DL, Bao R, Jimenez C, Grubbs EG, Lee JE, Evans DB. Posterior retroperitoneoscopic adrenalectomy: preferred technique for removal of benign tumors and isolated metastases. Ann Surg. 2008 Oct;248(4):666-74. doi: 10.1097/SLA.0b013e31818a1d2a.

    PMID: 18936580BACKGROUND
  • Walz MK, Alesina PF, Wenger FA, Deligiannis A, Szuczik E, Petersenn S, Ommer A, Groeben H, Peitgen K, Janssen OE, Philipp T, Neumann HP, Schmid KW, Mann K. Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery. 2006 Dec;140(6):943-8; discussion 948-50. doi: 10.1016/j.surg.2006.07.039.

    PMID: 17188142BACKGROUND
  • Constantinides VA, Christakis I, Touska P, Palazzo FF. Systematic review and meta-analysis of retroperitoneoscopic versus laparoscopic adrenalectomy. Br J Surg. 2012 Dec;99(12):1639-48. doi: 10.1002/bjs.8921. Epub 2012 Sep 28.

    PMID: 23023976BACKGROUND
  • Rubinstein M, Gill IS, Aron M, Kilciler M, Meraney AM, Finelli A, Moinzadeh A, Ukimura O, Desai MM, Kaouk J, Bravo E. Prospective, randomized comparison of transperitoneal versus retroperitoneal laparoscopic adrenalectomy. J Urol. 2005 Aug;174(2):442-5; discussion 445. doi: 10.1097/01.ju.0000165336.44836.2d.

    PMID: 16006861BACKGROUND
  • Barczynski M, Konturek A, Nowak W. Randomized clinical trial of posterior retroperitoneoscopic adrenalectomy versus lateral transperitoneal laparoscopic adrenalectomy with a 5-year follow-up. Ann Surg. 2014 Nov;260(5):740-7; discussion 747-8. doi: 10.1097/SLA.0000000000000982.

MeSH Terms

Conditions

Adrenal Gland NeoplasmsPheochromocytomaHyperaldosteronismCushing Syndrome

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsAdrenal Gland DiseasesEndocrine System DiseasesParagangliomaNeuroendocrine TumorsNeuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasms, Nerve TissueAdrenocortical Hyperfunction

Study Officials

  • Marcin Barczyński, MD, PhD

    Jagiellonian University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor of Surgery at the Third Chair of General Surgery

Study Record Dates

First Submitted

October 6, 2013

First Posted

October 10, 2013

Study Start

January 1, 2006

Primary Completion

June 1, 2008

Study Completion

July 1, 2013

Last Updated

October 10, 2013

Record last verified: 2013-10

Locations